Screener Summaries Updates Institutions Sign In More Updates › Other Events › PRAX Other Events · Jun 29, 2026
Praxis Precision Medicines, Inc. announced on June 29, 2026, that the FDA has extended the review period for its… PRAX Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. announced on June 29, 2026, that the FDA has extended the review period for its relutrigine New Drug Application (NDA) for treating SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) by three months. The updated PDUFA target action date is now December 27, 2026, following the FDA's classification of the Company's additional sensitivity analyses as a
More from Praxis Precision Medicines, Inc. Praxis Precision Medicines reported a net loss of $83.7 million for the second quarter ended June 30, 2026, compared… Aug 6, 2026 Praxis Precision Medicines, Inc. entered into a research collaboration and license agreement with Remagine Labs, Inc.… Jul 7, 2026 On June 29, 2026, the Audit Committee of Praxis Precision Medicines, Inc. dismissed Ernst & Young LLP (EY) as its… Jul 2, 2026 Praxis Precision Medicines, Inc. announced on June 22, 2026, that the U.S. Food and Drug Administration (FDA) granted… Jun 22, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
